Consider referring to a
today to see what’s
possible with DUPIXENT

When topical Rx therapies aren’t enough, DUPIXENT may be appropriate

Patients may be appropriate for DUPIXENT if they:

  • Have tried a variety of topical Rx therapies and are still uncontrolled
  • Suffer from inadequate control of pruritus
  • Have ≥10% of their body covered with lesions and/or may involve problem areas such as the face, hands, and feet
  • Have moderate-to-severe erythema and moderate-to-severe papulation/infiltration (IGA score of 3=moderate or 4=severe)

Consider referring your patients to a specialist today

Partner with an eczema specialist to help your patients. Use the HealthgradesTM tool to easily find nearby eczema specialists with experience in treating children (aged 6 to 11 years), adolescents (aged 12 to 17 years), and adults (aged 18+ years) with uncontrolled moderate-to-severe atopic dermatitis.

Unlike topical and oral corticosteroids, DUPIXENT
targets a source of underlying inflammation to proactively treat AD1,2

Atopic dermatitis is a chronic, recurring, and systemic disease, leaving patients trapped in an endless cycle of flares driven in part by persistent underlying inflammation2,3

Even when patients are not in a flare, they continue to experience underlying inflammation2

Topical Rx therapies may not be enough to treat moderate-to-severe atopic dermatitis2,4,5

DUPIXENT Is Revolutionizing
Atopic Dermatitis

DUPIXENT has proven efficacy and demonstrated long-term safety profile in moderate-to-severe atopic dermatitis uncontrolled with topical Rx therapy1

Itch relief1

Clear or almost-clear skin and improvement in lesion extent and severity1

Clinical trial outcomes supported by real-world data in adults1,6,7

Demonstrated safety profile1

DUPIXENT is not an immunosuppressant1

There is no requirement for initial lab testing or ongoing lab monitoring according to the Prescribing Information1

The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.1

Trial Designs and Results